Authors
Loading...
Ablating TRIM6 improves antitumor immunity and response to anti-PD-L1 therapy in MSS gastric cancer, highlighting novel pathways.
Niu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: